论文部分内容阅读
目的:研究大肠癌血清蛋白质谱的变化,从而筛选特异性蛋白标志物。方法:利用IMAC3蛋白质芯 片和SELDI-TOF质谱技术,对64例大肠癌病人和40名正常人的血清蛋白质谱进行分析。获得的蛋白质谱采用Ci phergen公司的Biomarker Wizard和Biomarker Pattern软件分析。结果:通过对大肠癌术前血清与正常人血清蛋白质谱 分析发现共有19个蛋白质表达量有明显差异。并获得分子量为5 972．67 D、5 927．21 D、6 113．48 D、5 908．55 D和 4 292．51 D这5个蛋白质组成的模板,可将大肠癌与正常人正确分组,其正确分组率分别为97．5％(56／64)和80％ (32／40)。术后血清蛋白质谱中,原高表达的蛋白质明显下调。结论:结果表明通过大肠癌手术前后及正常对照血清 中蛋白质谱的比较,筛选得到用以诊断大肠癌的特异性蛋白标志物并用以预后的判断。SELDI-TOF蛋白质芯片技 术为建立蛋白质模板从而早期诊断大肠癌提供了可靠的技术平台。
Objective: To study the changes of serum protein profiles in colorectal cancer and screen specific protein markers. Methods: Serum protein profiles of 64 patients with colorectal cancer and 40 normal controls were analyzed using IMAC3 protein chip and SELDI-TOF mass spectrometry. The protein profiles obtained were analyzed using BioPergen Biomarker Wizard and Biomarker Pattern software. Results: The protein profiles of 19 proteins in colorectal cancer serum were significantly different from those in normal people. The five proteins with the molecular weights of 5 972.67 D, 5 927.21 D, 6 113.48 D, 5 908.55 D and 4 292.51 D were obtained and used for the correct grouping of colorectal cancer and normal subjects , The correct grouping rates were 97.5% (56/64) and 80% (32/40), respectively. Postoperative serum protein profiles, the original high expression of protein was significantly down-regulated. Conclusion: The results showed that the protein profiles of colorectal cancer before and after surgery and normal control serum were screened to determine the specific protein markers for diagnosis of colorectal cancer and to predict the prognosis. SELDI-TOF protein chip technology for the establishment of protein templates to early diagnosis of colorectal cancer provides a reliable technology platform.